Pharmacokinetics of therapeutic monoclonal antibodies used in oncology.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Anticancer Research

• Publication date

  2005-05-01

• Fields of study

  Medicine

• Identifiers
  PMID 16080460
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gemtuzumab ozogamicin

  2012cited by this paper
• Cetuximab in the treatment of metastatic colorectal cancer

  2007cited by this paper
• Barrier ' ' Microscopic Tumor Nodules : Consequences of a ' ' Binding Site An Analysis of Monoclonal Antibody Distribution in Updated

  2006cited by this paper
• Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

  2006cited by this paper
• Radioimmunotherapy for Non-Hodgkin's Lymphoma.

  2005cited by this paper
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

  2004cited by this paper
• Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.

  2004cited by this paper
• Antibody-targeted radiation cancer therapy

  2004cited by this paper
• Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates*

  2004cited by this paper
• Cetuximab

  2004cited by this paper
• Biodistribution and pharmacokinetics of radiolabeled trastuzumab in HER2-positive metastatic breast cancer.

  2004cited by this paper
• Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.

  2004cited by this paper
• The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy

  2004cited by this paper
• Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.

  2004cited by this paper
• Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

  2004cited by this paper
• Clinical pharmacokinetics of bevacizumab following every 2- or every 3-week dosing.

  2004cited by this paper
• Subcutaneous Campath-1H (Alemtuzumab) in Fludarabine-Refractory Cll: Interim Analysis of the CLL2h Study of the German Cll Study Group (GCLLSG).

  2004cited by this paper
• A study to assess the pharmacokinetics (PK) of a single infusion of cetuximab (IMC-C225).

  2004cited by this paper
• Omalizumab

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma.

  2004cited by this paper
• Optimising alemtuzumab therapy for refractory B cell chronic lymphocytic leukaemia (CLL).

  2004cited by this paper
• Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas.

  2004cited by this paper
• Monoclonal antibodies as therapeutic agents for cancer.

  2004cited by this paper
• High interstitial fluid pressure — an obstacle in cancer therapy

  2004cited by this paper
• Monitoring of Serum Her-2/neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer

  2004cited by this paper
• Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.

  2004cited by this paper
• Visualizing the Site and Dynamics of IgG Salvage by the MHC Class I-Related Receptor, FcRn1

  2004cited by this paper
• Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer

  2004cited by this paper
• Pharmacokinetics of Gemtuzumab Ozogamicin as a Single‐Agent Treatment of Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

  2004cited by this paper
• Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia1

  2004cited by this paper
• Monoclonal antibodies market

  2004cited by this paper
• Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay.

  2004cited by this paper
• Pathology: Cancer cells compress intratumour vessels

  2004cited by this paper
• Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

  2004cited by this paper
• Feasibility of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy for Non-Hodgkin’s Lymphoma in a Patient with Chronic Renal Failure.

  2004cited by this paper
• Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti‐CD52 antibodies

  2004cited by this paper
• A population pharmacokinetic model for bevacizumab

  2004cited by this paper
• Radioimmunotherapy of non-Hodgkin lymphomas.

  2003cited by this paper
• Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment.

  2003cited by this paper
• Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans.

  2003cited by this paper
• Targeting HER1/EGFR: a molecular approach to cancer therapy.

  2003cited by this paper
• The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab.

  2003cited by this paper
• Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia.

  2003cited by this paper
• Expression of CD52 on plasma cells in plasma cell proliferative disorders.

  2003cited by this paper
• Crystalline monoclonal antibodies for subcutaneous delivery

  2003cited by this paper
• Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation.

  2003cited by this paper
• Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.

  2003cited by this paper
• Immunologic targets in psoriasis.

  2003cited by this paper
• Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

  2003cited by this paper
• Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients.

  2003cited by this paper
• Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications.

  2003cited by this paper
• The MHC class I related Fc receptor, FcRn, is expressed in the epithelial cells of the human mammary gland.

  2003cited by this paper
• An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.

  2003cited by this paper
• Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

  2003cited by this paper
• 90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.

  2003cited by this paper
• Trastuzumab: hopes and realities.

  2002cited by this paper
• Licensure of Gemtuzumab Ozogamicin for the Treatment of Selected Patients 60 Years of Age or Older with Acute Myeloid Leukemia in First Relapse

  2002cited by this paper
• Tumour biology: Herceptin acts as an anti-angiogenic cocktail

  2002cited by this paper
• Dissecting tumour pathophysiology using intravital microscopy

  2002cited by this paper
• Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

  2002cited by this paper
• Binding to CD20 by Anti-B1 Antibody or F(ab')2 is sufficient for induction of apoptosis in B-cell lines

  2002cited by this paper
• Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma

  2002cited by this paper
• FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells.

  2002cited by this paper
• Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.

  2002cited by this paper
• Intraventricular and Intravenous Treatment of a Patient with Refractory Primary CNS Lymphoma using Rituximab

  2002cited by this paper
• Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.

  2002cited by this paper
• Expression of the neonatal Fc receptor (FcRn) at the blood–brain barrier

  2002cited by this paper
• Pharmacokinetics of CAMPATH-1H: assay development and validation.

  2002cited by this paper
• Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.

  2002cited by this paper
• Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

  2002cited by this paper
• CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

  2002cited by this paper
• Complexation of VEGF with Bevacizumab Decreases VEGF Clearance in Rats

  2002cited by this paper
• Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers

  2002cited by this paper
• Treatment of a patient with end‐stage renal disease with Rituximab: Pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis

  2002cited by this paper
• Clinically useful monoclonal antibodies in treatment.

  2002cited by this paper
• CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

  2002cited by this paper
• Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

  2002cited by this paper
• Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function.

  2001cited by this paper
• Role of tumor–host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors

  2001cited by this paper
• Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

  2001cited by this paper
• Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.

  2001cited by this paper
• Pharmacokinetics of CAMPATH-1H in BMT patients.

  2001cited by this paper
• Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.

  2001cited by this paper
• Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma.

  2001cited by this paper
• The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans.

  2001cited by this paper
• Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier.

  2001cited by this paper
• Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.

  2001cited by this paper
• Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

  2001cited by this paper
• Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.

  2001cited by this paper
• Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

  2001cited by this paper
• Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies.

  2001cited by this paper
• Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse

  2001cited by this paper
• Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?

  2000cited by this paper
• Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture.

  2000cited by this paper
• Trastuzumab in CSF.

  2000cited by this paper
• Role of extracellular matrix assembly in interstitial transport in solid tumors.

  2000cited by this paper
• Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

  2000cited by this paper
• Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.

  2000cited by this paper
• Therapeutic monoclonal antibodies.

  2000cited by this paper

• Characterization and quantification of therapeutic monoclonal antibodies, anti-drug antibodies and their interactions for clinical applications

  2025cites this paper
• Antipolyphosphate monoclonal antibodies derived from autoimmune mice

  2024cites this paper
• No Interference of H9 Extract on Trastuzumab Pharmacokinetics in Their Combinations

  2023influential citation
• Plasma exchange as a tool for removal of bevacizumab: Highlighting application for urgent surgery.

  2023cites this paper
• Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies

  2021cites this paper
• In Situ Programming of CAR T Cells

  2021cites this paper
• A Computational Investigation of In Vivo Cytosolic Protein Delivery for Cancer Therapy

  2021cites this paper
• Intravenous and subcutaneous administration of trastuzumab in a patient on peritoneal dialysis

  2021cites this paper
• Production of the next-generation positron nuclide zirconium-89 (89 Zr) guided by Monte Carlo simulation and its good quality for antibody labeling.

  2020cites this paper
• Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders.

  2020cites this paper
• Pharmacokinetic Evaluation of Nimotuzumab in Patients With Autosomal Dominant Polycystic Kidney Disease

  2019cites this paper
• Key Physicochemical Characteristics Influencing ADME Properties of Therapeutic Proteins.

  2019cites this paper
• Photonuclear production, chemistry, and in vitro evaluation of the theranostic radionuclide 47Sc

  2019cites this paper
• Impact of a Heat Shock Protein Impurity on the Immunogenicity of Biotherapeutic Monoclonal Antibodies

  2019cites this paper
• False-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab: Potential Pitfalls for the Misdiagnosis of B-Cell Neoplasms

  2018cites this paper
• Biodistribution and Tumor Uptake of 67Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft

  2018cites this paper
• Simultaneous evaluation of anti-EGFR-induced tumour and adverse skin effects in a microfluidic human 3D co-culture model

  2018cites this paper
• Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study

  2017cites this paper
• A novel model for the pharmacokinetic studies of bevacizumab and etanercept in healthy volunteers and patients

  2017cites this paper
• Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma

  2017cites this paper
• Population pharmacokinetic meta‐analysis of ramucirumab in cancer patients

  2017cites this paper
• First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

  2017cites this paper
• Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer

  2017cites this paper
• Influence of Escherichia coli chaperone DnaK on protein immunogenicity

  2016cites this paper
• Fate of Multimeric Oligomers, Submicron, and Micron Size Aggregates of Monoclonal Antibodies Upon Subcutaneous Injection in Mice.

  2016cites this paper
• Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization

  2015cites this paper
• Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia

  2015cites this paper
• Clinical and Preclinical Use of LOX-1-Specific Antibodies in Diagnostics and Therapeutics

  2015cites this paper
• Biopharmaceutical Products from Animal Cell Culture

  2015cites this paper
• Radiolabelling and biodistribution of IgE antibodies

  2015cites this paper
• Otlertuzumab (TRU‐016), an anti‐CD37 monospecific ADAPTIR™ therapeutic protein, for relapsed or refractory NHL patients

  2015cites this paper
• Subcellular drug targeting, pharmacokinetics and bioavailability

  2014cites this paper
• Subcutaneous administration of anticancer agents.

  2014cites this paper
• Genetic Modification of Neurons to Express Bevacizumab for Local Anti-angiogenesis Treatment of Glioblastoma

  2014cites this paper
• Anti–Prostate-Specific Membrane Antigen Liposomes Loaded with 225Ac for Potential Targeted Antivascular α-Particle Therapy of Cancer

  2014cites this paper
• Targeted drug delivery for cancer therapy

  2013cites this paper
• A Humanized Monoclonal Antibody Specific for Invariant Natural Killer T (iNKT) Cells for In Vivo Depletion

  2013cites this paper
• Bevacizumab for the Treatment of Glioblastoma

  2013cites this paper
• Systemic and biophase bioavailability and pharmacokinetics of nanoparticulate drug delivery systems.

  2013cites this paper
• Sex differences in the drug therapy for oncologic diseases.

  2012cites this paper
• Targeted drug delivery for cancer therapy: the other side of antibodies

  2012cites this paper
• Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology.

  2011cites this paper
• Etica médica y humanismo

  2010cites this paper
• Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab

  2010cites this paper
• Terapéutica con agentes biológicos y riesgo de infecciones oportunistas

  2010cites this paper
• Clinical pharmacology of trastuzumab.

  2008cites this paper
• Evaluation of fixed dosing of new anticancer agents in phase I studies.

  2008cites this paper
• Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing Mice

  2006cites this paper
• Synergistic AntitumorActivity ofTaxol and Immunotoxin SS1P inTumor-BearingMice

  2006cites this paper
• Phase I Dose Escalation Study To Evaluate the Safety and Pharmacokinetic Profile of Tefibazumab in Subjects with End-Stage Renal Disease Requiring Hemodialysis

  2006cites this paper
• Subcutaneous Administration of Anticancer Agents: A Narrative Review

  year unknowncites this paper